THE WOODLANDS, Texas, July 30, 2012 (GLOBE NEWSWIRE) -- Repros
Therapeutics Inc.(R) (Nasdaq:RPRX) today announced the FDA has
scheduled a meeting to discuss the design of a Phase 2 endometriosis
protocol for low dose oral Proellex(R). The teleconference will be held
during the last week of August 2012. The Company has submitted the
Phase 2 protocol for FDA review. The Company looks forward to the
Agency's advice.

About Repros Therapeutics Inc. (R)

Repros Therapeutics focuses on the development of small molecule drugs
for major unmet medical needs that treat male and female reproductive
disorders.

The Repros Therapeutics Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7738

Any statements made by the Company that are not historical facts
contained in this release are forward-looking statements that involve
risks and uncertainties, including the ability to raise additional
needed capital on a timely basis in order for it to continue to fund
development of its Androxal(R) and Proellex(R) programs, have success
in the clinical development of its technologies, the reliability of
interim results to predict final study outcomes, and such other risks
which are identified in the Company's most recent Annual Report on Form
10-K and in any subsequent quarterly reports on Form 10-Q. These
documents are available on request from Repros Therapeutics or at
www.sec.gov. Repros disclaims any intention or obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.

For more information, please visit the Company's website at
http://www.reprosrx.com.


CONTACT: Repros Therapeutics Inc.
         Joseph Podolski (281) 719-3447
         President and Chief Executive Officer
         
         Investor Relations: Thomas Fechtner
         The Trout Group
         (646) 378-2931